DNER and acute myeloid leukemia: The in vivo efficacy of JQ1 or other BET-targeting drugs for MDS patients is currently unknown, even though preliminary experimental and clinical data from BET inhibition in AML patients showed that BET-targeting drugs presented low toxicity profile and promising efficacy.